Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new partnership has been formed between the Universities of Oxford and Birmingham to speed up the development of novel treatments for arthritis, supported by a £7 million investment from the Kennedy Trust for Rheumatology Research.

Drug discovery © Sisacorn - Shutterstock

A new partnership to speed up the development of novel treatments for arthritis has been launched, supported by a £7 million investment from the Kennedy Trust for Rheumatology Research.

The partnership between the Universities of Oxford and Birmingham will be based at the Kennedy Institute of Rheumatology at Oxford and the Institute of Translational Medicine in Birmingham.  It will harness the existing research strengths of both universities in order to accelerate the development and testing of new therapies for patients. The Arthritis Therapy Acceleration Programme (A-TAP) will develop and test therapies based on the underlying causes of inflammatory disease, rather than simply treating the clinical symptoms.

Read more

Similar stories

Labelling proteins through the diet gives new insights into how collagen-rich tissues change as we age

A new study, published in eLife, uses advanced tissue analysis technology to show how the incorporation of new proteins changes in bone and cartilage with age.

Drug could help diabetic hearts recover after heart attack - Oxford research

Researchers at the University of Oxford have identified a drug that could ultimately help improve heart function in people with diabetes who have heart attacks.

Largest ever global study of tuberculosis identifies genetic causes of drug resistance

Using cutting-edge genomic sequencing techniques, researchers at the University of Oxford have identified almost all the genomic variation that gives people resistance to 13 of the most common tuberculosis (TB) drug treatments.

Peter Horby receives prestigious award for outstanding service to public health

The Faculty of Public Health (FPH) has awarded its prestigious Alwyn Smith Prize to Professor Sir Peter Horby (Nuffield Department of Medicine) for 2020/2021 in recognition of his outstanding service to public health as a global leader in epidemic science.

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.